6CM
CNTB

683 Capital Management’s Connect Biopharma Holdings CNTB Stock Holding History

683 Capital Management’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
1,285,000
+385,000
+43% +$933K 0.15% 86
2026
Q1 		$2.36M Buy
+900,000
New +$2.35M 0.12% 99

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

683 Capital Management's CNTB Position: Q2 2026 in Review

683 Capital Management increased its Connect Biopharma Holdings (CNTB) stake by 43% in Q2 2026, buying an estimated $933K and bringing the position to 1,285,000 shares worth $3.06M. The position accounts for 0.15% of the portfolio, ranked #86.

683 Capital Management first reported a position in CNTB in Q1 2026 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • 683 Capital Management held 1,285,000 shares of Connect Biopharma Holdings worth $3.06M as of Q2 2026.
  • 683 Capital Management bought 385,000 Connect Biopharma Holdings shares in Q2 2026, an estimated $933K.
  • Connect Biopharma Holdings made up 0.15% of 683 Capital Management's portfolio in Q2 2026, its #86 holding.
  • 683 Capital Management first reported a position in Connect Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.